Simon Read, Director at Dianthus Therapeutics, Inc. /DE/ (DNTH), sold 2,777 shares at $107.11 ($304K) on 2026-08-10, disclosed to the SEC on 2026-08-11.
Scheduled sale ($304k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $107.11 | 70 | $7K | 2.5% |
| 2 | $108.17 | 737 | $80K | 26.2% |
| 3 | $108.95 | 831 | $91K | 29.8% |
| 4 | $109.96 | 272 | $30K | 9.8% |
| 5 | $111.05 | 470 | $52K | 17.2% |
| 6 | $111.77 | 397 |
| $44K |
| 14.6% |
| Total | $109.55 avg | 2,777 | $304K | 100% |
| Filing → |
| RARX | SELL | 2019-11-18 | $467K | — | Filing → |
| RARX | SELL | 2019-10-17 | $469K | — | Filing → |
| RARX | SELL | 2019-09-16 | $254K | — | Filing → |